Answers are grounded in this paper and cite their sources.
Originally, light-to-moderate alcohol consumption was believed to provide some protective effects on the cardiovascular system through its antioxidant properties and other constituents; this was illustrated through the longstanding J-shaped curve association between alcohol consumption and the incidence of cardiovascular disease (Gillman et al., 1995). However, more recent meta-analyses and genome-wide association studies reveal that a paradigm shift from the beneficial to harmful effects of alcohol consumption has occurred after taking into account other confounders, such as the participants' background and lifestyle (Biddinger et al., 2022). Furthermore, it has been well established that chronic heavy alcohol usage causes oxidative stress and systemic inflammation, which deteriorates cardiac function over time through a myriad of cellular and organ-level perturbations, resulting in fibrosis development (Bishehsari et al., 2017). As a result, inhibiting inflammation has become a treatment strategy to restore myocardial function and prevent fibrosis progression induced by alcohol consumption. Thromboxane A2 receptor (TPR), a G-protein-coupled receptor, is ubiquitously expressed in multiple organs and cell types including platelets, macrophages, monocytes, and vascular endothelial cells (Giannarelli et al., 2010). Upon activation through a myriad of ligands including 8-iso prostaglandin (8-iso) and/or thromboxane A2 (TXA2), produced primarily by platelets (Smyth, 2010), TPR signaling can result in cytoskeleton alterations, platelet adhesion, and vesicle trafficking to induce platelet activation (Ting et al., 2012). Thus, mutations and dysregulation of TPR signaling play a role in the pathogenesis of several cardiovascular diseases, including myocardial infarction, stroke, atherosclerosis, and thrombosis (Rucker & Dhamoon, 2019). As a result, TPR presents as a promising therapeutic target, and many believe that developing the appropriate TPR antagonists would provide significant efficacy in modulating cardiovascular-related diseases, including alcohol-induced cardiomyopathy. Ai et al. (2024) explored the role of TPR signaling in alcohol-mediated cardiac inflammation and TPR antagonism as a treatment for early cardiac injury. The group utilized a mouse model of chronic plus binge ethanol exposure that has been extensively studied and characterized to mimic alcohol use disorders in humans (NIAAA model) (Bertola et al., 2013). In this model, 8-week-old mice were fed ethanol for 10 days, followed by one binge of ethanol. A cohort of mice in the study received a TPR antagonist, SQ29,548, during their 10 days of ethanol feeding. Measurement of various inflammatory, oxidative stress, cardiac remodeling, and fibrosis biomarkers were the primary endpoints. The group confirmed the inflammatory and oxidative stress responses induced by alcohol using only rudimentary molecular techniques, limiting the evidence on which they based their conclusions. Additional studies using flow cytometric quantification of myocardial immune cell infiltrates and/or histological assessment could provide a more substantial set of results confirming the biomarker findings. The exclusion of functional cardiac measurements raises questions about the cardiac physiological state after a 10-day binge-on-chronic ethanol and the utility of this early cardiac inflammatory phenotype, as described by the authors, to predict future outcomes in the presence or absence of TPS antagonism. The addition of rigorous physiological testing, which could include invasive hemodynamics, endurance exercise testing, or cardiac ultrasound analysis, would allow for observing any phenotypical changes due to the augmentation of these early molecular markers. In the end, the investigators exhibited the attenuating effects of SQ29,548 in reducing markers for oxidative stress, inflammation, and fibrosis compared with ethanol-fed controls. These results suggest that TPR antagonism is potentially an effective treatment for alcoholic cardiomyopathy. Although researchers have successfully developed TPR antagonists, none are FDA-approved; targeting TPR in humans remains elusive (Jourdi et al., 2021). An upstream treatment strategy involving the thromboxane pathway includes using cyclooxygenase inhibitors such as aspirin, which relies on inhibiting the TPR agonist TXA2. Aspirin inhibits COX-1, which is expressed by platelets, to reduce the biosynthesis of TXA2 (Roth et al., 1975). However, aspirin can cause nonspecific COX inhibition to disrupt the maintenance of the endothelium, resulting in gastrointestinal erosions, renal, and hepatic insufficiency (Suleyman et al., 2007). This type of nonspecificity has limited the clinical utility of current TPR-related pharmacotherapies. Most discovered TPR antagonists remain pharmacological research tools for uncovering TPR-mediated signaling events in various pathological pathways (Ting et al., 2012). Most notably, the pharmacological compound SQ29,548 presents as a highly selective TPR antagonist that helped researchers' study TPR's role in human platelet aggregation and animal disease models of asthma, rhinitis, and brain ischemia (Ogletree et al., 1985; Ting et al., 2012). Yet, TPR antagonists fail to extend beyond stage I/II of clinical trials with concerns for toxicity and effectiveness in humans (Savage et al., 1995; Serruys et al., 1991). Ultimately, TPR antagonists persist as a powerful research tool, yet they currently lack clinical utility. Researchers continue exploring TPR's role in various pathological pathways and attempting to redesign therapeutics to improve its translational profile, especially in cardiovascular diseases in which TPR expression and signaling are known to induce cardiac inflammation. In vascular and atherothrombotic diseases, TPR stimulates endothelial production of superoxide anions and reactive oxygen/nitrogen species through eNOS uncoupling, leading to the generation of oxidative stress and endothelial dysfunction (Zhang et al., 2011). Furthermore, TXA2 binds to C-EL2, a ligand binding domain of TPR, to mediate platelet aggregation in humans in vitro and murine ex vivo (Murad et al., 2012). In contrast, TPR activation is also involved in oligodendrocyte maturation as TPRs localize to the nuclear compartment during oligodendrocyte differentiation (Ramamurthy et al., 2006). A renewal of interest in studying the pharmacophore features of TPR antagonists in humans and performing docking simulations of TPR antagonists through artificial intelligence could pave the way for novel and more effective antagonist designs (Hu et al., 2020). To solidify the role of the TPR antagonist as a viable treatment option, future studies need to improve its selectivity and cell/organ specificity. In addition, most TPR-related studies are currently done in rodent models (Xiao et al., 2001; Xie et al., 2017; Zuccollo et al., 2005). Given the evolutionary variation of TPR isoforms between rodents, large mammals, and humans, more relevant preclinical testing, which mimics the human variants and signaling, should be explored to produce more meaningful observations. With the renewed interest in drugging TPR signaling cascades, Ai et al. (2024) provides preliminary findings demonstrating, yet another disease pathology with which TPR antagonism may be a viable therapeutic target. In addition to the treatment of alcohol-induced inflammation and cardiomyopathy, successful implementation of TPR antagonism may lead to a new therapeutic strategy for modern-day cardiovascular-related diseases, including hypertension, obesity, diabetes, and heart failure. As this area of therapeutic interest attempts to resurrect itself from its historical stagnation (Ting et al., 2012), we hope that further and more rigorous studies will provide substantiation of the observation made by Ai et al. The authors (TES & TTV) have no conflicts of interest to disclose.
No takes yet. Share an insight, caveat, or question.
Sharp et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: